Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02638961
Other study ID # IMT-FES 01
Secondary ID
Status Completed
Phase N/A
First received December 1, 2015
Last updated May 17, 2017
Start date October 2015
Est. completion date March 2017

Study information

Verified date May 2017
Source Universitat Jaume I
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart failure (HF) with preserved ejection fraction (HFpEF) has become the most prevalent form of HF in developed countries. Despite its increasing in prevalence, there is no evidence-based effective therapy for HFpEF The purpose of this study was to evaluate whether inspiratory muscle training (IMT), functional electrical stimulation (FES), or combination of both improve exercise capacity as well as left ventricular diastolic function, biomarkers' profile, quality of life (QoL) and prognosis in patients with HFpEF.


Description:

This study was designed as a prospective, controlled, randomized, four-armed, efficacy trial of patients with the diagnosis of HFpEF and New York Heart Association functional class II-III/IV, diagnosed according to criteria of the European Society of Cardiology. A computer-generated randomization scheme was used to allocate participants (in a 1:1:1:1 ratio) to receive: 1) a home-based 12-week program of inspiratory muscle training (IMT) or; 2) a 12-week program of functional electrical stimulation (FES) of lower limb muscles or; 3) standard treatment (ST) alone or; 4) combination of IMT and FES. The study is being conducted in a single center in Spain. Independently of staggered entry, the minimum duration of a patient's participation is 6 months (from first to last visit). All patients will provide signed informed consent and the protocol has been approved by the research ethics committee of our center in accordance with the principles of the Declaration of Helsinki and national regulations.

Study population Candidate patients are selected from the outpatient's clinics of HF of the Hospital Clínico Universitario of Valencia.

Study objectives The primary endpoint of the study is a clinical endpoint of three and six months change in peak oxygen uptake (peak VO2).

Secondary endpoints are three and six month changes in echocardiogram parameters, QoL and prognostic biomarkers. The investigators also will specifically focus on number of episodes of worsening HF at 6 months:

1. Change in E/e' after three and six months.

2. Change in left atrial volume index after three and six months.

3. Change in health-related QoL measured by the Minnesota Living With Heart Failure Questionnaire (MLHF) after three and six months.

4. Change in natriuretic peptide (NT-proBNP) after three and six months.

5. Change in minute ventilation/carbon dioxide production (VE/VCO2) slope after three and six months.

6. Number of episodes of acute HF hospitalizations and number of episodes of worsening HF not requiring hospitalization at 6 months.

Intervention

Eligibility assessment and screening visit After reviewing the inclusion/exclusion criteria and signing the informed consent form, a comprehensive medical history, physical examination, anthropometry and examination tests will be performed. The examination tests include: electrocardiogram (ECG) echocardiography, cardiopulmonary exercise testing (CPET), 6-minute walk test (6-MWT), inspiratory muscle function test, QoL assessment by the Minnesota Living With Heart Failure Questionnaire (MLHF) and blood samples for a panel of baseline biomarkers.

Finally, patients are randomized (1:1:1:1) to four groups: 1) ST alone or; 2) a home-based 12-week program of IMT or; 3) a 12-week program of FES or; 4) combination of IMT and FES (IMT+FES) during 12 weeks.

12-week and six months visits All patients will be evaluated after 12-week supervised training, and six months after randomization. Evaluation will include medical history, physical examination, anthropometry and functional and QoL assessment tests (ECG, CPET, 6-MWT, inspiratory muscle function test, MLHF and blood tests).


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date March 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Previous history of symptomatic heart failure NYHA (New York Heart Association )functional class =II with Normal left ventricular ejection fraction:

- ejection fraction >0.50 by Simpson method

- end-diastolic diameter <60 mm

- Structural heart disease:

- left ventricle hypertrophy/left atrial enlargement and/or

- diastolic dysfunction estimated by 2D echocardiography

- Previous admission for acute heart failure

- Clinical stability, without hospital admissions in the past 3 month

Exclusion Criteria:

- Perform a valid baseline exercise test

- Significant primary moderate to severe valvular disease

- Acute coronary syndrome or cardiac surgery within the previous three months

- Signs of ischemia during cardiopulmonary exercise testing

- Significant primary pulmonary disease; including pulmonary arterial hypertension, chronic thromboembolic pulmonary disease or chronic obstructive pulmonary disease

- Any other comorbidity with an expectancy of life less than one year

Study Design


Related Conditions & MeSH terms


Intervention

Other:
IMT
Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
FES
Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
Standard treatment
Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.

Locations

Country Name City State
Spain Hospital clínico universitario de Valencia Valencia

Sponsors (3)

Lead Sponsor Collaborator
Universitat Jaume I Hospital Clínico Universitario de Valencia, INCLIVA

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Palau P, Domínguez E, Núñez E, Schmid JP, Vergara P, Ramón JM, Mascarell B, Sanchis J, Chorro FJ, Núñez J. Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2014 Dec;21(12):1465-73. doi: 10.1177/2047487313498832. Epub 2013 Jul 17. — View Citation

Palau P, Núñez E, Domínguez E, Sanchis J, Núñez J. Physical therapy in heart failure with preserved ejection fraction: A systematic review. Eur J Prev Cardiol. 2016 Jan;23(1):4-13. doi: 10.1177/2047487314562740. Epub 2014 Dec 8. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Functional capacity measured as peak oxygen uptake (peak VO2) in ml/min/kg . Maximal functional capacity will be evaluated with an incremental and symptom-limited cardiopulmonary exercise testing (CORTEX Metamax 3B) on a bicycle ergometer, beginning with a workload of 10 W and increasing stepwise at 10-W increments every 1 min. During exercise, patients were continuously monitored with twelve-lead electrocardiogram and blood pressure measurements every 2 min. Gas exchange data and cardiopulmonary variables were averaged every 10 seconds values. Peak VO2 is considered the highest value of VO2 during the last 20 s of exercise.
The improvement > of 10% in peak VO2 will be considered clinically meaningful
changes at 12 weeks and 6 months
Secondary Functional capacity measured as distance walked in 6 minutes Patients will be instructed to cover the maximum distance (meters) possible in six minutes, at a self-graded walking speed, pausing to rest when needed. Each subject will undergo 4 tests. The goal of the first one was to allow the patient to familiarize with the test. changes at 12 weeks and 6 months
Secondary Change in echocardiographic parameter of diastolic disfunction: e' septal (cm/s) Doppler echocardiogram examination of e' septal (cm/s) will be performed under resting conditions using 2D echocardiography (iE33, Philips). e' septal (cm/s) parameter will be measured according to current guidelines of the European Society of Echocardiography:
Only significant improvements in this parameter will be considered
changes in rest at 12 weeks and 6 months
Secondary Change in echocardiographic parameter of diastolic disfunction: left atrial volume index (mm/m2) Doppler echocardiogram examination of left atrial volume index (mm/m2) will be performed under resting conditions using 2D echocardiography (iE33, Philips). Left atrial volume index (mm/m2) will be measured according to current guidelines of the European Society of Echocardiography.
Only significant improvements in this parameter will be considered
changes in rest at 12 weeks and 6 months
Secondary Change in echocardiographic parameter of diastolic disfunction: E/e' ratio Doppler echocardiogram examination of E/e' ratio will be performed under resting conditions using 2D echocardiography (iE33, Philips). E/e' ratio parameter will be measured according to current guidelines of the European Society of Echocardiography.
Only significant improvement in this parameter will be considered
changes in rest at 12 weeks and 6 months
Secondary Change in health-related QoL Change in health-related QoL will be measured by the Minnesota Living With Heart Failure Questionnaire (no units) Only significant improvements in these parameters will be considered changes at 12 weeks and 6 months
Secondary Number of rehospitalizations or worsening HF at 6 months Number of episodes of acute HF hospitalizations and number of episodes of worsening HF not requiring hospitalization at 6 months among different arms. changes at 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT02459626 - Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Completed NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT03871803 - β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) Phase 4
Completed NCT03672591 - Renal Hemodynamics in Patients With HFpEF
Recruiting NCT03620526 - Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Phase 4
Active, not recruiting NCT03624010 - Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients Phase 2
Completed NCT03541603 - Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF Phase 2
Completed NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Completed NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03186833 - The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
Completed NCT03289481 - Treatment of HFpEF With Nitrate Supplement Early Phase 1
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Completed NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea
Completed NCT03966755 - Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF N/A
Not yet recruiting NCT04282850 - Ablation Versus Medical Management of Atrial Fibrillation in HFpEF N/A
Recruiting NCT03184311 - High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction N/A
Withdrawn NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure